Drugs / ISIS 353512
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00734240 | Jul 2008 → Feb 2010 | inflammatory disease | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISIS 353512 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00734240 ↗ |
| Route | Intravenous | “ISIS 353512 Administered Intravenously and Subcutaneously to Healthy Volunteers” NCT00734240 ↗ |
| Route | Subcutaneous | “ISIS 353512 Administered Intravenously and Subcutaneously to Healthy Volunteers” NCT00734240 ↗ |